Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with the Portacath.

M E Lambert1, G A Chadwick, A McMahon

  • 1Department of Medical Oncology, Christie Hospital, Manchester, U.K.

Hematological Oncology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USPIO enhanced MR imaging in CNS tumors (UMIC): a study protocol.

Nanomedicine (London, England)·2026
Same author

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation.

bioRxiv : the preprint server for biology·2026
Same author

Commonly encountered central nervous system infections in the intensive care unit.

BJA education·2023
Same author

A review of approaches to <sup>18</sup> F radiolabelling affinity peptides and proteins.

Journal of labelled compounds & radiopharmaceuticals·2018
Same author

Determination of Total Biotin by Liquid Chromatography Coupled with Immunoaffinity Column Cleanup Extraction: Multilaboratory Testing, Final Action 2016.02.

Journal of AOAC International·2017
Same author

Development of a method for the preparation of zirconium-89 radiolabelled chitosan nanoparticles as an application for leukocyte trafficking with positron emission tomography.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2017
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Portacaths provide reliable vascular access for chemotherapy patients. Proper management by trained staff ensures the safe and effective long-term use of these devices, minimizing complications.

Area of Science:

  • Oncology
  • Vascular Surgery
  • Medical Devices

Background:

  • Prolonged outpatient chemotherapy requires reliable vascular access.
  • Hematological diseases often necessitate long-term treatment regimens.
  • Central venous access devices are crucial for administering chemotherapy.

Purpose of the Study:

  • To evaluate the safety and reliability of Portacaths in patients undergoing prolonged outpatient chemotherapy.
  • To identify factors contributing to Portacath dysfunction and complications.
  • To assess the long-term performance of Portacaths in a clinical setting.

Main Methods:

  • Retrospective analysis of 50 Portacath insertions in patients receiving chemotherapy.
  • Documentation of device functionality, duration of use, and reasons for removal.

Related Experiment Videos

  • Review of complications, including suspected infections and occlusions.

    • Main Results:

    • Twenty-one Portacaths remained functional at a median of 12 months; 15 functioned until patient death (median survival 6 months).
    • Four functioning devices were removed: three for suspected sepsis, one for erroneous occlusion diagnosis.
    • Ten devices failed, nine of which were removed; most failures were avoidable, particularly early in experience.

    Conclusions:

    • Portacaths are safe and reliable for intermittent vascular access when managed meticulously.
    • Careful attention to detail and experienced staff are critical for successful Portacath utilization.
    • Many Portacath failures are preventable, emphasizing the importance of proper management protocols.